

Cancer Prevention and Control Central IRB

Meeting Agenda

**Thursday, March 22, 2018
9:00am –11:45am Eastern Time**

I. Study Chair Response to Tabled Initial Review

NWU2017-09-01, Phase I Trial of Endoxifen Gel versus Placebo Gel in Women Undergoing Breast Surgery (Protocol Version Date 03/08/2018)

II. Continuing Review

MAY2015-05-01, Randomized, Double-blind, Placebo-controlled Trial of Meriva™ (curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis.” (Protocol Version Date 10/6/17)

III. Participant Materials Review

NWU2015-06-01, Evaluating Intermittent Dosing of Aspirin for Colorectal Cancer Chemoprevention (Protocol Version Date 10/30/2017)

IV. Participant Materials Review

NRG-CC004, Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer (Protocol Version Date 09/08/2017)

V. Amendment Review

NWU2015-06-02, Immunogenicity of Nonavalent HPV Vaccine Administered Prior To Living Donor Renal Transplantation in Adult Women: A Prospective, Single-Arm, Multi-Center Clinical Trial (Protocol Version Date 03/07/2018)

VI. Amendment Review

MDA2017-09-03, Pilot study of denosumab in BRCA1/2 mutation carriers scheduling risk-reducing salpingoophorectomy (Protocol Version Date 02/28/2018)

VII. Amendment Review

UAZ2015-05-01, A prospective, single-arm, open-label, non-randomized, phase IIA trial of a nonavalent prophylactic HPV vaccine to assess immunogenicity of a prime and deferred-booster dosing schedule among 9-11 year-old girls and boys (Protocol Version Date 03/06/2018)
